Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | PTGES | O14684 | 1/20 | 0.31 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.30 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7052307 | 0.84 | ALDH1A1 (0.33) | ALDH1A1MAPTHPGDLMNAPTGES | |
| SCHEMBL7049851 | 0.82 | AKR1C2 (0.38) | ALDH1A1MAPTHPGDLMNAPTGES | |
| SCHEMBL7052349 | 0.81 | MAPT (0.35) | ALDH1A1MAPTHPGDLMNAPTGES | |
| SCHEMBL7049824 | 0.77 | HPGD (0.36) | ALDH1A1MAPTHPGDAGTR1AGTR2 | |
| SCHEMBL7076349 | 0.76 | BCL2L1 (0.43) | LMNAPTGES | |
| SCHEMBL7048489 | 0.76 | POLB (0.43) | ALDH1A1MAPTHPGDAGTR1AGTR2 | |
| SCHEMBL7051028 | 0.75 | POLB (0.42) | HPGDAGTR1AGTR2 | |
| SCHEMBL7076569 | 0.71 | SMPD1 (0.53) | — | |
| SCHEMBL7050676 | 0.69 | HDAC8 (0.34) | ALDH1A1HPGD | |
| SCHEMBL7077602 | 0.66 | PTGES (0.53) | ALDH1A1LMNAPTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030191323-A1 | Hypoglycemic agent | AJINOMOTO CO., INC. (JP) | 2003-10-09 | — | — | US | disclosed |
| US-20030162818-A1 | Acylsulfonamide derivative | AJINOMOTO CO. INC. (JP) | 2003-08-28 | — | — | US | disclosed |
| US-6555584-B1 | Acetyl-coa carboxylase inhibitors | AJINOMOTO CO., INC. (JP) | 2003-04-29 | — | — | US | disclosed |
| EP-1300142-A1 | HYPOGLYCEMICS | Ajinomoto Co., Inc. (JP) | 2003-04-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162818-A1 | Acylsulfonamide derivative | ACSS2, ACACA, FASN | ALDH1A1 385/4885MAPT 3922/4885HPGD 3434/4885 |
| US-20030191323-A1 | Hypoglycemic agent | GPR119, IAPP, SLC5A2 | ALDH1A1 410/4885MAPT 4390/4885HPGD 1451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.